Money Talks: Why weight-loss drugs will reshape the world
More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that can help people shed up to a fifth of…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Economist Podcasts →
Novo Nordisk, Eli Lilly and the GLP-1 economy
Here's How the New Weight Loss Drugs Could Change Everything
The Weight Loss Drug Revolution: Transforming Bodies and Reshaping Economies | The Global Brief
Can weight loss drugs reduce healthcare costs?
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.